-
.
- Pyxis Oncology Inc PYXS(* )accepted get Apexigen Inc APGN in an all-stock purchase for an indicated worth of $ 0.64 per Apexigen share. .
- .(* )For every share of Apexigen, Pyxis Oncology will certainly provide 0.1725 shares of its ordinary shares for a complete business worth of roughly $16 million.went .
- .
- .
- .
- .
- .(* )The purchase is prepared for to nearby mid-2023.
- .
- right into a globally permit contract with
- for 2 antibody-drug conjugate (ADC) prospects and also a permit to Pfizer’s ADC modern technology system.entered
. Rate Activity: APGN shares are up 39.5% at $0.56, and also PYXS shares are down 8.92% at $3.40 on the last check Wednesday.
.
© 2023 Benzinga.com. Benzinga does not supply financial investment guidance. All legal rights booked.
Apexigen(* )public in a blank-check bargain simply last summertime.
In February, Apexigen introduced examining choices and also lowered its labor force by 55%.
” This purchase distinctly places Pyxis Oncology at the center of antibody-drug conjugate (ADC) development by including humanized antibody generation to our Adaptable Antibody Conjugation Innovation (REALITY) ADC toolkit obtained from Pfizer,” claimed Lara S. Sullivan, Head Of State & & Chief Executive Officer of Pyxis Oncology.
Pyxis Oncology finished Q1 FY23 with roughly $ 150.8 million in money.
Efficient June 15, 2023, Jay Feingold will certainly tip down as Principal Medical Policeman to seek various other chances. He will certainly continue to be an expert to Pyxis Oncology till a follower is called.
Pyxis Oncology anticipates to provide roughly 4.4 million shares of its ordinary shares to Apexigen shareholders.
.(* )The consolidated business will certainly trade on Nasdaq under the ticker icon PYXS. The existing Pyxis Oncology management group will certainly proceed, consisting of Lara S. Sullivan as Head Of State & & CHIEF EXECUTIVE OFFICER, Pamela Connealy as CFO & & COO, and also Jan Pinkas as Principal Scientific Police Officer.
In 2021, Pyxis Oncology
Pfizer Inc
PFE
